I lead the Pyramax project, which is MMV's second submission to the European Medicines Agency for regulatory approval.
Why I work at MMV:
To be able to use my competencies for a cause such as malaria and to take part in the development of a new antimalarial which will save lives is a huge motivation. In fact, for me it’s a privilege.
More about me:
I have extensive experience in clinical and medical research. Before joining MMV, I spent 10 years in clinical development in the biotech Industry, at Serono International SA, developing drugs for various indications in auto-immune diseases and hemato-oncology. Before that I spent 10 years in academia, working in hyperlipidemias and diabetes.
Ask me about:
Clinical development plans, clinical trials from design to set-up & implementation through to analysis and reporting, EMA’s Article 58 procedure, GCP inspections, partnerships.
Isabelle holds a PhD in Biochemistry from the University of Geneva.